Tocilizumab in patients with Takayasu arteritis: A retrospective study and literature review

Clinical and Experimental Rheumatology

Volumn 34, Issue , 2016, Pages S44-S53

  Loricera, Javier ^a   Blanco, Ricardo ^a   Hernández, José L ^a   Castañeda, Santos ^b   Humbría, Alicia ^b   Ortego, Norberto ^c   Bravo, Beatriz ^d   Freire, Mercedes ^e   Melchor, Sheila ^f   Mínguez, Mauricio ^g   Salvatierra, Juan ^c   González Vela, Carmen ^a   Calvo Río, Vanesa ^a   Santos Gómez, Montserrat ^a   Pina, Trinitario ^a   González Gay, Miguel A ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^e HOSPITAL JUAN CANALEJO   (Spain)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

Author keywords

Biological therapy; Large vessel vasculitis; Takayasu arteritis; Tocilizumab

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; FLUORODEOXYGLUCOSE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLATE MOFETIL; PENTRAXIN 3; PREDNISONE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AORTA ARCH SYNDROME; ARTICLE; CEREBROVASCULAR DISEASE; CHILD; CLAUDICATION; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; IMAGE ANALYSIS; MAINTENANCE THERAPY; MALAISE; MESENTERIC ISCHEMIA; MULTICENTER STUDY; MYALGIA; NODULAR SCLEROSIS; ONSET AGE; OPEN STUDY; PRIORITY JOURNAL; REFRACTORY TAKAYASU ARTERITIS; RETROSPECTIVE STUDY; SCHOOL CHILD; SCLERITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; UPPER LIMB CLAUDICATION; CLINICAL TRIAL; MIDDLE AGED; TAKAYASU ARTERITIS;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; FEMALE; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; TAKAYASU ARTERITIS;

EID: 84984830302     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (85)

1. JENNETTE JC, FALK RJ, BACON PA et al. 2012 Revised International Chapel Hill Consensous Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65: 1-11.
2. PéREZ-ESTEBAN S, GONZáLEZ-GAY MA, CASTAñEDA S. Therapeutic update in large vessel vasculitides. Rev Clin Esp 2013; 213: 338-46.
3. MASON JC. Takayasu arteritis: advances in diagnosis and management. Nat Rev Rheumatol 2010; 6: 406-15.
4. SALVARANI C, CANTINI F, BOIARDI L, HUNDER GG. Polymialgia rheumatic and giant-cell arteritis. N Engl J Med 2002; 347: 261-71.
5. GONZALEZ-GAY MA, GARCIA-PORRUA C, LLORCA J et al. Visual manifestations of giant cell arteritis: trends and clinical spectrum in 161 patients. Medicine (Baltimore) 2000; 79: 283-92.
6. GONZALEZ-GAY MA, GARCIA-PORRUA C. Epidemiology of the vasculitides. Rheum Dis Clin North Am 2001; 27: 729-49.
7. GONZALEZ-GAY MA, VAZQUEZ-RODRIGUEZ TR, LOPEZ-DIAZ MJ et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009; 61:1454-61.
8. JOHNSTON SL, LOCK RJ, GOMPELS MM. Takayasu arteritis: a review. J Clin Pathol 2002; 55:481-6.
9. HALL S, BARR W, LIE JT, STANSON AW, KAZMIER FJ, HUNDER GG. Takayasu arteritis: a study of 32 North American patients. Medicine (Baltimore) 1985; 64: 89- 99.
10. GORNIK HL, CREAGER MA. Aortitis. Circulation 2008; 117: 3039-51.
11. GONZALEZ-GAY MA, PINEIRO A, GOMEZGIGIREY A et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore) 2004; 83: 342-7.
12. WEN D, DU X, MA CS. Takayasu arteritis: diagnosis, treatment and prognosis. Int Rev Immunol 2012; 31: 462-73.
13. EVANS JM, ÓFALLON WM, HUNDER GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis: a population-based study. Ann Intern Med 1995; 122: 502-7.
14. GONZáLEZ-GAY MA, GARCíA-PORRúA C, PIñEIRO A, PEGO-REIGOSA R, LLORCA J, HUNDER GG. Aortic aneurysm and dissec tion in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population- based study. Medicine (Baltimore) 2004; 83: 335-41.
15. KERR GS, HALLAHAN CW, GIORDANO J et al. Takayasu arteritis. Ann Intern Med 1994; 120: 919-29.
16. KERR GS. Takayasu's arteritis. Rheum Dis Clin North Am 1995; 21: 1041-58.
17. MISRA R, DANDA D, RAJAPPA SM et al. INDIAN RHEUMATOLOGY VASCULITIS (IRAVAS) GROUP: Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford) 2013; 52: 1795-801.
18. HATA A, NUMANO F. Magnetic resonance imaging of vascular changes in Takayasu arteritis. Int J Cardiol 1995; 52: 45-52.
19. MATSUMARA K, HIRANO T, TAKEDA K et al. Incidence of aneurysms in Takayasu's arteritis. Angiology 1991; 42: 308-15.
20. KöTTER I, HENES JC, WAGNER AD, LOOK J, GROSS WL. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol 2012; 30 (Suppl. 70): 114-29.
21. HENES JC, MUELLER M, PFANNENBERG C, KANZ L, KOETTER I. Cyclophosphamide for large vessel vasculitis: assessment of response by PET/CT. Clin Exp Rheumatol 2011; 29 (Suppl. 64): 43-8.
22. MAKSIMOWICZ-MCKINNON K, CLARK TM, HOFFMAN GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 2007; 56: 1000-9.
23. JAIN S, KUMARI S, GANGULY NK, SHARMA BK. Current status of Takayasu arteritis in India. Int J Cardiol 1996; 54 (Suppl.): 111-6.
24. SOTO ME, ESPINOLA N, FLORES-SUAREZ LF, REYES PA. Takayasu arteritis: clinical features in 110 Mexican Mestizo patients and cardiovascular impact on survival and prognosis. Clin Exp Rheumatol 2008; 26 (Suppl. 49): 9-15.
25. HOFFMAN GS, LEAVITT RY, KERR GS, ROTTEM M, SNELLER MC, FAUCI AS. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994; 37: 578-82.
26. DAINA E, SCHIEPPATI A, REMUZZI G. Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases. Ann Intern Med 1999; 130: 422-6.
27. HOFFMAN GS, MERKEL PA, BRASINGTON RD, LENSCHOW DJ, LIANG P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004; 50: 2296-304.
28. HOFFMAN GS, CID MC, RENDT-ZAGAR KE, et al. Infliximab for maintenance of glucocorticosteroid- induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007; 146: 621-30.
29. MARTíNEZ-TABOADA VM, RODRíGUEZVALVERDE V, CARREñO L, et al. A doubleblind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008; 67: 625-30.
30. MOLLOY ES, LANGFORD CA, CLARK TM, GOTA CE, HOFFMAN GS. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term followup. Ann Rheum Dis 2008; 67: 1567-69.
31. SCHAFER VS, ZWERINA J. Biologic treatment of large-vessel vasculitides. Curr Opin Rheumatol 2012; 24: 31-7.
32. DELLA ROSSA A, TAVONI A, MERLINI G, et al. Two Takayasu arteritis patients successfully treated with infliximab a potential diseasemodifying agent? Rheumatology (Oxford) 2005; 44: 1074-5.
33. KARAGEORGAKI ZT, MAVRAGANI CP, PAPATHANASIOU MA, SKOPOULI FN. Infliximab in Takayasu arteritis: a safe alternative? Clin Rheumatol 2007; 26: 984-7.
34. TANAKA F, KAWAKAMI A, IWANAGA N, et al. Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate. Intern Med 2006; 45: 313-6.
35. TATO F, RIEGER J, HOFFMANN U. Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab. Int Angiol 2005; 24: 304-7.
36. PAZZOLA G, PADOVANO I, BOIARDI L, et al. Tocilizumab in glucocorticoid-naïve large-vessel vasculitis. Case report. Clin Exp Rheumatol 2013; 31 (Suppl. 75): 59-61.
37. BEYER C, AXMANN R, SAHINBEGOVIC E et al. Antiinterleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis 2011; 70: 1874-5.
38. CHRISTIDIS D, JAIN S, DAS GUPTA B. Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement. BMJ Case Reports 2011; doi:10.1136/bcr.04.2011.4135
39. NISHIMOTO N, NAKAHARA H, YOSHIOHOSHINO N, MIMA T. Successful treatment of a patient with Takayasu arteritis using a humanized antiinterleukin-6 receptor antibody. Arthritis Rheum 2008; 58: 1197-200.
40. SALVARANI C, MAGNANI L, CATANOSO M et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 2012; 51: 151-6.
41. SEITZ M, REICHENBACH S, BONEL HM, ADLER S, WERMELINGER F, VILLIGER PM. Rapid induction of remission in large vessel vasculitis by IL-6 blockade: a case series. Swiss Med Wkly 2011; 141: w13156.
42. UNIZONY S, ARIAS- URDANETA L, MIOSLAVSKY E, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatic. Arthritis Care Res (Hoboken) 2012; 64: 1720-9.
43. QUARTUCCIO L, SCHIAVON F, ZULIANI F, et al. Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's arteritis treated with infliximab. Clin Exp Rheumatol 2012; 30: 922-8.
44. SCHMIDT J, KERMANI TA, BACANI AK, CROWSON CS, MATTESON EL, WARRINGTON KJ. Tumor necrosis factor inhibitors in patients with Takayasu arteritis experience from a referral center with long-term follow. Arthritis Care Res (Hoboken) 2012; 64: 1079-83.
45. COMARMOND C, PLAISIER E, DAHAN K, et al. Anti TNF-alpha in tefractory Takayasu's arteritis: cases series and review of the literature. Autoimmun Rev 2012; 11: 678-84.
46. ABISROR N, MEKINIAN A, LAVIGNE C, et al. Tocilizumab in tefractory Takayasu arteritis: a case series and updated literature review. Autoimmun Rev 2013; 12: 1143-9.
47. BREDEMEIER M, ROCHA CM, BARBOSA MV, PITREZ EH. One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab. Clin Exp Rheumatol 2012; 30 (Suppl. 70): 98-100.
48. XENITIDIS T, HORGER M, ZEH G, KANZ L, HENES JC. Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritis. Rheumatology (Oxford) 2013; 52: 1729-31.
49. TOMBETTI E, FRANCHINI S, PAPA M, SABBADINI MG, BALDISSERA E. Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center. J Rheumatol 2013; 40: 2047-51.
50. YOUNGSTEIN T, PETERS JE, HAMLUDAY SS et al. Serial analysis of clinical and imaging indices reveals prolonged efficacy of TNF-a and IL-6 receptor targeted therapies in refractory Takayasu arteritis. Clin Exp Rheumatol 2014; 32 (Suppl. 82): 11-8.
51. SALVARANI C, MAGNANI L, CATANOSO M et al. Rescue treatment with Tocilizumab for Takayasu arteritis resistant to TNF-a blockers. Clin Exp Rheumatol 2012; 30 (Suppl. 70): 90-3.
52. CHAUHAN SK, TRIPATHY NK, NITYANAND S. Antigenic targets and pathogenicity of antiaortic endothelial cell antibodies in Takayasu. Arthritis Rheum 2006; 54: 2326-33.
53. MAFFEI S, DI RENZO M, BOVA G, AUTERI A, PASQUI AL. Takayasu's arteritis: a review of the literature. Intern Emerg Med 2006; 1: 105-12.
54. PARK MC, LEE SW, PARK YB, LEE SK. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford) 2006; 45: 545-8.
55. WEYAND CM, GORONZY JJ. Giant cell arteritis: pathogenesis. In: HOFFMAN GS, WEYAND CM (Eds.) Inflammatory diseases of blood vessels. New York: Marcel Dekker 2002: 413-23.
56. WEYAND CM, GORONZY JJ. Medium- and Large-Vessel Vasculitis. N Engl J Med 2003; 349:160-9.
57. LORICERA J, BLANCO R, CASTAñEDA S, et al. Tocilizumab in refractory aortitis: study on 16 patients and literature review. Clin Exp Rheumatol 2014; 32 (Suppl. 82): 79-89.
58. LORICERA J, BLANCO R, HERNáNDEZ JL, et al. Non-infectious aortitis: a report of 32 cases from a single tertiary centre in a 4-year period and literature review. Clin Exp Rheumatol 2015; 33 (Suppl 89): S19-31.
59. LORICERA J, BLANCO R, HERNáNDEZ JL, et al. Tocilizumab in giant cell arteritis: multicenter open-label study of 22 patients. Semin Arthritis Rheum 2015; 44: 717-23.
60. DAYER JM, CHOY E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology 2010; 49: 15-24.
61. AREND WP, MICHEL BA, BLOCH DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990; 33: 1129-34.
62. HOYER BF, MUMTAZ IM, LODDENKEMPER K, et al. Takayasu arteritis is characterized by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 2012; 71: 75-9.
63. WANG H, MA J, WU Q, LUO X, CHEN Z, KOU L. Circulating B lymphocytes producing autoantibodies to endothelial cells play a role in the pathogenesis of Takayasu arteritis. J Vasc Surg 2011; 53: 174-80.
64. GALARZA C, VALENCIA D, TOBON GJ, et al. Should rituximab be considered as the firstchoice treatment for severe autoimmune rheumatic diseases? Clin Rev Allergy Immunol 2008; 34: 124-8.
65. ERNST D, GREER M, STOLL M, MEYER-OLSON D, SCHMIDT RE, WITTE T. Remission achieved in refractory advanced Takayasu arteritis using rituximab. Case Rep Rheumatol 2012; 2012: 406963.
66. SEKO Y, SATO O, TAKAGI A et al. Restricted usage of T-cell receptor Valpha- Vbeta genes in infiltrating cells in aortic tissue of patients with Takayasu's arteritis. Circulation 1996; 15; 93: 1788-90.
67. ALIBAZ-ONER F, YENTüR SP, SARUHANDIRESKENELI G, DIRESKENELI H. Serum cytokine profiles in Takayasu's arteritis: search for biomarkers. Clin Exp Rheumatol 2015; 33 (Suppl 89): S32-5.
68. TOMBETTI E, DI CHIO MC, SARTORELLI S et al. Anti-cytokine treatment for Takayasu arteritis: State of the art. Intractable Rare Dis Res 2014; 3: 29-33.
69. DAGNA L, SALVO F, TIRABOSCHI M, et al. Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann Intern Med 2011; 155: 425-33.
70. OSMAN M, PAGNOUX C, DRYDEN DM, STORIE D, YACYSHYN E. The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis. PLoS One 2014; 9: e 115026.
71. CAñAS CA, CAñAS F, IZQUIERDO JH, et al. Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis. J Clin Rheumatol 2014; 20: 125-9.
72. CABERO MOYANO J, ANDREU MAGAROLAS M, CASTAñER GONZáLEZ E, GALLARDO CISTARé X, BELMONTE CASTAN E. Nonurgent aortic disease: Clinical-radiological diagnosis of aortitis. Radiologia 2013; 55: 469-82.
73. PIPITONE N, VERSARI A, SALVARANI C. Role of imaging studies in the diagnosis and follow-up of large-vessel vasculitis. Rheumatology (Oxford) 2008; 47: 403-8.
74. RESTREPO CS, OCAZIONEZ D, SURI R, VARGAS D. Aortitis: imaging spectrum of the infectious and inflammatory conditions of the aorta. Radiographics 2011; 31: 435-51.
75. SCHEEL AK, MELLER J, VOSSHENRICH R, et al. Diagnosis and follow up of aortitis in the elderly. Ann Rheum Dis 2004; 63: 1507-10.
76. TAKAHASHI T, ANDO M, OKITA Y, TAGUSARI O, HANABUSA Y, KITAMURA S. Redo aortic valve replacement with "porcelain" aorta in an aortitis patient: a case report. J Cardiovasc Surg (Torino) 2005; 46: 77-9.
77. KISSING EY, MERKEL PA. Diagnostic imaging in Takayasu arteritis. Curr Opin Rheumatol 2004; 16: 31-7.
78. TSO E, FLAMM SD, WHITE RD, SCHVARTZMAN PR, MASCHA E, HOFFMAN GS. Takayasu arteritis: utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum 2002; 46: 1634-42.
79. BLOCKMANS D, STROOBANTS S, MAES A, MORTELMANS L. Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am J Med 2000; 108: 246-9.
80. FUCHS M, BRIEL M, DAIKELER T, et al. The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. Eur J Nucl Med Mol Imaging 2012; 39: 344-53.
81. MARTíNEZ-RODRíGUEZ I, DEL CASTILLOMATOS R, QUIRCE R, et al. Aortic 18F-FDG PET/CT uptake pattern at 60 (early) and 180 (delayed) acquisition in a control population: Visual and semiquantitative comparative analysis. Nucl Med Commun 2013; 34: 926-30.
82. MARTíNEZ-RODRíGUEZ I, DEL CASTILLOMATOS R, QUIRCE R, et al. Comparison of early (60 min) and delayed (180 min) acquisition of 18F-FDG PET/CT in large vessel vasculitis. Rev Esp Med Nucl Imagen Mol 2013; 32: 222-6.
83. MARTíNEZ-RODRíGUEZ I, MARTíNEZAMADOR N, BANZO I, et al. Assessment of aortitis by semiquantitative analysis of 180-min 18F-FDG PET/CT acquisition images. Eur J Nucl Med Mol Imaging 2014; 41: 2319-24.
84. MARTíNEZ-RODRíGUEZ I, DEL CASTILLOMATOS R, RUBIO-VASSALLO A, ORTEGANAVA F, MARTíNEZ-AMADOR NA, CARRIL JM. Diagnosis and assessment of the treatment response in a case of giant cell arteritis using 18F-FDG PET/CT. Rev Esp Med Nucl Imagen Mol 2012; 31: 233-5.
85. MELLER J, STRUTZ F, SIEFKER U, et al. Early diagnosis and follow-up of aortitis with [(18)F] FDG PET and MRI. Eur J Nucl Med Mol Imaging 2003; 30: 730-6.